Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.

A number of other brokerages have also recently issued reports on ADMS. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Cowen and Company reissued an “outperform” rating and issued a $45.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Mizuho reissued a “buy” rating and issued a $26.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Finally, Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $27.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 0.23% on Wednesday, reaching $17.66. 114,827 shares of the company were exchanged. The firm’s market capitalization is $394.86 million. The firm has a 50-day moving average of $17.25 and a 200 day moving average of $16.83. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $19.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 45.19%. During the same period in the prior year, the firm earned ($0.65) EPS. On average, equities analysts predict that Adamas Pharmaceuticals will post ($3.47) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/23/adamas-pharmaceuticals-inc-nasdaqadms-downgraded-to-sell-at-bidaskclub.html.

In other news, major shareholder Great Point Partners Llc sold 350,000 shares of the stock in a transaction on Monday, June 19th. The shares were sold at an average price of $17.05, for a total value of $5,967,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 731,041 shares of company stock valued at $12,476,149. Corporate insiders own 29.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Adamas Pharmaceuticals by 10.3% in the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after buying an additional 66,825 shares during the last quarter. State Street Corp boosted its position in Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock valued at $2,138,000 after buying an additional 28,994 shares during the last quarter. Geode Capital Management LLC boosted its position in Adamas Pharmaceuticals by 4.9% in the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after buying an additional 5,920 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares during the last quarter. 71.43% of the stock is owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.